Faecal calprotectin

Authors: D. Kamenář;  J. Špičák
Authors‘ workplace: Institut klinické a experimentální medicíny, Praha, Klinika hepatogastroenterologie, Přednosta: prof. MUDr. Julius Špičák, CSc.
Published in: Prakt. Lék. 2011; 91(11): 665-669
Category: Diagnostis


Calprotectin is a calcium-binding protein contained in neutrophils. Inflammatory damage of the intestinal mucosa causes an influx of neutrophils into the intestinal lumen, after which increased calprotectin levels can be measured in stools. Calprotectin in faeces is a good marker of inflammation and disease activity in inflammatory bowel disease, and is suitable for assessment of disease course, monitoring of treatment effect and probably predicting relapses. Normalization of faecal calprotectin seems to be a strong indicator of healing of the intestinal mucosa. Calprotectin is of some differential diagnostic value in patients with irritable bowel syndrome and it can make indications to colonoscopy more accurate in these patients.

Key words:
calprotectin, Crohn disease, inflammatory bowel disease, irritable bowel disease, ulcerative colitis.


1. Bunn, S.K., Bisset, W.M., Main, M.J., Golden, B.E. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2001, 32, p. 171-177.

2. Fagerberg, U.L., Lööf, L., Merzoug, R.D. et al. Fecal calprotectin levels in healthy children studied with an improved assay. J. Pediatr. Gastroenterol. Nutr. 2003, 37, p. 468-472.

3. Fliedner, S.H., Cronkite, E.P., Robertson, J.S. Granulopoesis, senescence and random loss of neutrophilic granulocytes in human beings. Blood 1964, 24, p. 404-414.

4. Steinbakk, M., Naess-Andresen, C.F., Lingaas, E. et al. Antimicrobial action of a calcium binding leukocyte L-1 protein, calprotectin. Lancet 1990, 336, p. 763-765.

5. Isaksen, B., Fagerhol, M.K. Calprotectin inhibits matrix metalloproteinases by sequestration of zinc. Mol. Pathol. 2001, 54, p. 289-292.

6. Yui, S., Mikami, M., Yamazaki, M. Induction of apoptotic cell death in mouse lymphoma and human leukemia cell lines by a calcium-binding complex, calprotectin, derived from inflammatory peritoneal exudate cells. J. Leukoc. Biol. 1995, 58, p. 650-658.

7. Berntzen, H.B., Olmez, U., Fagerhol, M.K. et al. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand. J. Rheumatol. 1991, 20, p. 74-82.

8. Røseth, A.G., Fagerhol, M.K., Aadland, E. et al. Assessment of the neutrophil dominating protein calprotectin in feces. Scand. J. Gastroenterol. 1992, 27, p. 793-798.

9. Bunn, S.K., Bisset, W.M., Main, M.J.C. et al. Faecal calprotectin: Validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2001, 33, p. 14-22.

10. Fagerberg, U.L., Lööf, L., Lindholm, J. et al. Fecal calprotectin: A quantitative marker of colonic inflammation in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 2007, 45, p. 414-420.

11. Fagerhol, M.K., Dale, I., Andersson, T. Release and quantification of a leucocyte derived protein (L1). Scand. J. Haematol. 1980, 24, p. 393-398.

12. Tøn, H., Brandsnes, O., Dale, S. et al. Improved assay for fecal calprotectin. Clin. Chem. Acta 2000, 292, p. 41-54.

13. Røseth, A.G., Schmidt, P.N., Fagerhol, M.K. Correlation between faecal excretion of indium-111-labeled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 1999, 34, p. 50-54.

14. Costa, F., Mumolo, M.G., Bellini, M. et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver. Dis. 2003, 35, p. 642-647.

15. Limburg, P.J., Ahlquist, D.A., Sandborn, W.J. et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am. J. Gastroenterol. 2000, 95, p. 2831-2837.

16. Montalto, M., Santoro, L., Curgliano, V. et al. Faecal calprotectin concentrations in untreated celiac patients. Scand. J. Gastroenterol. 2007, 42, p. 957-961.

17. Drossman, D.A., Camilleri, M., Mayer, E.A. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123, p. 2108-2131.

18. Suleiman, S., Sonnenberg, A. Cost-effectiveness of endoscopy in irritable bowel syndrome. Arch. Intern. Med. 2001, 161, p. 369-375.

19. Longstreth, G.F., Thompson, W.G., Chey, W.D. et al. Functional bowel disorders. Gastroenterology 2006, 130, p. 1480-1491.

20. Camilleri, M., Williams, D.E. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000, 17, p. 331-338.

21. Tibble, J., Teahon, K., Thjodleifsson, B. et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut 2000, 47, p. 506-513.

22. Carroccio, A., Iacono, G., Cottone, M. et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin. Chem. 2003, 49, p. 861-867.

23. Fagerberg, U.L., Lööf, L., Myrdal, U. et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J. Pediatr. Gastroenterol. Nutr. 2005, 40, p. 450-455.

24. von Roon, A.C., Karamountzos, L., Purkayastha, S. et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol. 2007, 102, p. 803-813.

25. Sipponen, T., Savilathi, E., Kolho, K.L. et al. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn’s disease activity index and endoscopic findings. Inflamm. Bowel Dis. 2007, 13, p. 1-7.

26. Jahnsen, J., Røseth, A.G., Aadland, E. Measurement of calprotectin in faeces. Tidsskr. Nor. Laegeforen. 2009, 129(8), p. 743-745.

27. Vermeeire, S., van Assche, G., Rutgeerts, P. Laboratory markers in IBD; useful, magic, or unnecessary toys? Gut 2006, 55, p. 426-431.

28. Røseth, A.G., Aadland, E., Jahnsen, J. et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997, 58, p. 176-180.

29. Brignola, C., Campieri, M., Bazzocchi, G. et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease. Gastroenterology 1986, 91(6), p. 1490-1494.

30. Boirivant, M., Leoni, M., Tariciotti, D. et al. The clinical significance of serum C reactive protein levels in Crohn’s disease. Results of a prospective longitudinal study. J. Clin. Gastroenterol. 1988, 10(4), p. 401-405.

31. Consigny, Y., Modigliani, R., Colombel, J.F. et al. Biological markers of short term relapse in Crohn’s disease (CD). Inflamm. Bowel Dis. 2006, 12(7), p. 551-557.

32. Travis, S.P., Farrant, J.M., Ricketts, C. et al. Predicting outcome in severe ulcerative colitis. Gut 1996, 38(6), p. 905-910.

33. Tibble, J.A., Sigthorsson, G., Bridger, S. et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000, 119, p. 15-22.

34. Costa, F., Mumolo, M.G., Ceccarelli, L. et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005, 54(3), p. 364-368.

35. D’Inca, R., Dal Pont, E., Di Leo, V. et al. Can calprotectin predict relapse in inflammatory bowel disease? Am. J. Gastroenterol. 2008, 103(8), p. 2007-2014.

36. Bitton, A., Peppercorn, M.A., Antonioli, D.A. Clinical, biological and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120, p. 13-20.

37. Rutgeerts, P., Diamond, R.H., Bala, M. et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest. Endosc. 2006, 63, p. 433-442.

38. Frøslie, K.F., Jahnsen, J., Moum, B.A. et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133, p. 412-422.

39. Røseth, A.G., Aadland, E., Grzyb, K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2004, 39, p. 1017-1020.

General practitioner for children and adolescents General practitioner for adults
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account